Seegnal to Deploy its Medication Safety Platform Across Nazareth Hospital EMMS, Expanding its Israeli Hospital Footprint

About this update from Seegnal Inc.

Historic regional trauma center and teaching hospital adopts Seegnal's patient-specific clinical decision support, expanding the Company's footprint across Israel's healthcare system CALGARY, AB, June 25, 2026 (GLOBE NEWSWIRE) -- Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Company"), a developer of innovative healthcare technology focused on mitigating medication risks, today announced that its Israeli operating subsidiary, Seegnal eHealth Ltd., has signed an agreement (the "Agreement") to deploy Seegnal's clinical decision support platform across Nazareth Hospital EMMS ("Nazareth Hospital" or the "Hospital"), one of the oldest hospitals in northern Israel that has served the Galilee for more than 160 years. Under the Agreement, Seegnal's platform will be integrated directly into Nazareth Hospital's clinical workflows, supporting approximately 424 members of the medical team, including approximately 188 physicians and 236 nurses, as part of routine, day-to-day prescribing. The Agreement, dated June 18, 2026, provides for an initial five-year term, with an option to extend, and for recurring subscription fees payable to Seegnal over the term. "Nazareth Hospital has stood at the heart of healthcare in the Galilee for more than 160 years, and we are honored to equip its clinicians with the same patient-specific medication safety standard now used by approximately 15,000 clinicians across Israeli hospitals and HMOs,"1 said Elad Bibi-Aviv, Chief Executive Officer of Seegnal. "Bringing Seegnal to a leading regional trauma center and teaching hospital is a meaningful step in our continued expansion across the Israeli healthcare system, and reflects our focus on delivering clinical and economic value at the point of care." Founded in 1861 by the Edinburgh Medical Missionary Society (EMMS) and operated today by The Nazareth Trust, Nazareth Hospital is one of the oldest hospitals in the region and the largest in Nazareth. It serves as the district general hospital and main trauma center for Nazareth and the surrounding towns and villages, a catchment area of approximately 570,000 people, and is a teaching hospital affiliated with Bar-Ilan University, training the next generation of physicians and nurses in northern Israel. With this Agreement, Nazareth Hospital becomes the latest Israeli healthcare organization to deploy Seegnal's platform. Adverse drug events are a leading cause of patient harm, with roughly one in twenty patients affected by preventable medication-related harm globally.2 Seegnal's SaaS-based platform integrates patient-specific data at the point of care, including current medications, laboratory results, renal function, diagnoses, age, and allergies, to deliver more precise, context-aware alerts that go well beyond traditional drug-to-drug interaction checks. The platform has been evaluated in prior peer-reviewed studies conducted at other institutions. In a peer-reviewed study at Brigham & Women's Hospital, Seegnal produced 94% fewer inpatient alerts than a conventional system, with 99% specificity.3 In a separate peer-reviewed controlled trial at Leumit Health Services, Seegnal was associated with 5.6% fewer hospitalizations and a roughly 1.5% reduction in total medications dispensed, with physicians resolving 42% of the severe drug-safety risks the platform identified.4 These results were observed in other care settings and are not necessarily indicative of the outcomes that may be achieved at Nazareth Hospital.

View stock analysis, news, and events for Seegnal Inc.